Esomeprazole relieves upper gastrointestinal symptoms in high-risk and average-risk NSAID users in daily clinical practice: Results from an open-label study

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 3, 2012, Pages 281-287

  Tielemans, Merel M ^a   Van Oijen, Martijn G H ^a,b   Mulder, Chris J J ^c   Vos, Kees J ^d   Lems, Willem F ^c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Clinical practice; gastrointestinal risk; nonsteroidal anti inflammatory drugs; proton pump inhibitor; upper gastrointestinal symptoms

Indexed keywords

ACECLOFENAC; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS PARACETAMOL; ARTHROTEC; CARBASALATE CALCIUM; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DEXIBUPROFEN; DICLOFENAC; ESOMEPRAZOLE; ETORICOXIB; IBUPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; SULINDAC; TIAPROFENIC ACID; UNCLASSIFIED DRUG; VALDECOXIB;

ADULT; AGED; ARTICLE; AVERAGE RISK PATIENT; BLOATING; CLINICAL PRACTICE; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEARTBURN; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER GASTROINTESTIAL SYMPTOM; UPPER GASTROINTESTINAL SYMPTOM;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84856745320     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32834f4d19     Document Type: Article

References (28)

1. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343:769-772. (Pubitemid 24098698)
2. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282:1929-1933.
3. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247-1255.
4. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 24: 1888-1899. (Pubitemid 29272670)
5. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996; 156:1530-1536.
6. Wiklund I. Quality of life in arthritis patients using nonsteroidal anti-inflammatory drugs. Can J Gastroenterol 1999; 13:129-133. (Pubitemid 29178644)
7. Lanas A, Hirschowitz BI. Toxicity of NSAIDs in the stomach and duodenum. Eur J Gastroenterol Hepatol 1999; 11:375-381. (Pubitemid 29199836)
8. Ofman JJ, Maclean CH, Straus WL, Morton SC, Berger ML, Roth EA, et al. Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs. Arthritis Rheum 2003; 49:508-518. (Pubitemid 36992191)
9. Newcastle Guideline Development and Research Unit. Dyspepsia: managing dyspepsia in adults in primary care NICE Clinical guideline 17. London: National Institute for Health and Clinical Excellence; Available at: http://www.nice.org.uk/CG017NICEguideline. [Accessed 1 July 2011]; 2004.
10. Talley NJ, Vakil N. Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005; 100:2324-2337.
11. Hawkey CJ, Talley NJ, Yeomans ND, Jones R, Sung JJ, Langström G, et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 2005; 100:1028-1036. (Pubitemid 40769038)
12. Hawkey CJ, Jones RH, Yeomans ND, Scheiman JM, Talley NJ, Goldstein JL, et al. Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2007; 25:813-821. (Pubitemid 46434908)
13. Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101: 701-710.
14. Brass EP. The gap between clinical trials and clinical practice: the use of pragmatic clinical trials to inform regulatory decision making. Clin Pharmacol Ther 2010; 87:351-355.
15. Chan FK, Abraham NS, Scheiman JM, Laine L. First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol 2008; 103:2908-291 8.
16. Hawkey CJ, Karrasch JA, Szczepañski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338: 727-734. (Pubitemid 28115091)
17. Agrawal NM, Campbell DR, Safdi MA, Lukasik NL, Huang B, Haber MM. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med 2000; 160:1455-1461. (Pubitemid 30327448)
18. Herings RM, Goettsch WG. Inadequate prevention of NSAID-induced gastrointestinal events. Ann Pharmacother 2004; 38:760-763. (Pubitemid 38509048)
19. Sturkenboom MC, Burke TA, Dieleman JP,Tangelder MJ, Lee F, Goldstein JL. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 2003; 42 (Suppl 3):iii23-iii31. (Pubitemid 37407011)
20. Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medication? Results of the patient unmet needs survey. J Clin Outcome Manage 2000; 7:29-34. (Pubitemid 33208979)
21. Jones R, Liker HR, Ducrotté P. Relationship between symptoms, subjective wellbeing and medication use in gastro-esophageal reflux disease. Int J Clin Pract 2007; 61:1301-1307. (Pubitemid 47052376)
22. Meineche-Schmidt V, Hauschildt Juhl H, Østergaard JE, Luckow A, Hvenegaard A. Costs and efficacy of three different esomeprazole treatment strategies for long-term management of gastro-esophageal reflux symptoms in primary care. Aliment Pharmacol Ther 2004; 19:907-915. (Pubitemid 38534820)
23. Dutch college of general practitioners. NHG clinical practice guideline M 36: gastric complaints. Huisarts Wet 2003; 46(12):690-700.
24. Talley NJ,Vakil NPractice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005; 100:2324-2337.
25. Talley NJ, Silverstein MD, Agréus L, Nyrén O, Sonnenberg A, Holtmann GAGA. Technical review: evaluation of dyspepsia. Gastroenterology 1998; 114:582-595.
26. Armstrong D. Helicobacter pylori infection and dyspepsia. Scand J Gastroenterol 1996; 31 (Suppl 215):38-47. (Pubitemid 26126023)
27. Mc Coll KEL. Helicobacterpylori infection. N Engl J Med 2010; 362:1597-1604.
28. Holtmann G, van Rensburg C, Schwan T, Sander P, Siffert W. Improvement of non-steroidal anti-inflammatory drug-induced gastrointestinal symptoms during proton pump inhibitortreatment: are G-Protein ß3 Subunit genotype, Helicobacter pylori status, and environmental factors response modifiers? Digestion 2011; 84:289-298.